Shots:

• The approval is based on P-lll COAST-X study assessing Taltz (80mg- q4w) vs PBO for the treatment of adult patients with nr-axSpA with objective signs of inflammation for 52wks.
• Result: 1EPs of ASAS40 @16wks. (35% vs 19%); ASAS40 response @52wks. (30% vs 13%)- met its 2EPs- showing efficacy in reducing disease activity and sacroiliac joint inflammation- improving patient function & QoL- the safety profile is consistent with the previous study
• Taltz is a mAb that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor

 ­ Ref: Newswire Canada | Image: Everyday Health